Blepharitis - Pipeline Review, H2 2011

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Blepharitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Blepharitis 7
Blepharitis Therapeutics under Development by Companies 9
Blepharitis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Blepharitis Therapeutics - Products under Development by Companies 15
Blepharitis Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Blepharitis Therapeutics Development 17
Lux Biosciences, Inc. 17
Galderma S.A. 17
InSite Vision Incorporated 18
LABORATOIRES THEA 18
Blepharitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
AzaSite Plus - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
AzaSite Xtra - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DexaSite - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Interleukin-1-Receptor Antagonist - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LX214 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Azyter - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LX212 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
COL-101 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Blepharitis Therapeutics – Drug Profile Updates 32
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 35
Contact Us 35
Disclaimer 35

List of Tables

Number of Products Under Development for Blepharitis, H2 2011 7
Products under Development for Blepharitis – Comparative Analysis, H2 2011 8
Number of Products under Development by Companies, H2 2011 9
Number of Products under Investigation by Universities/Institutes, H2 2011 10
Comparative Analysis by Late Stage Development, H2 2011 11
Comparative Analysis by Mid Clinical Stage Development, H2 2011 12
Comparative Analysis by Early Clinical Stage Development, H2 2011 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2011 14
Products under Development by Companies, H2 2011 15
Products under Investigation by Universities/Institutes, H2 2011 16
Lux Biosciences, Inc., H2 2011 17
Galderma S.A., H2 2011 17
InSite Vision Incorporated, H2 2011 18
LABORATOIRES THEA, H2 2011 18
Assessment by Monotherapy Products, H2 2011 19
Assessment by Stage and Route of Administration, H2 2011 21
Assessment by Molecule Type, H2 2011 23
Blepharitis Therapeutics – Drug Profile Updates 32

List of Figures

Number of Products under Development for Blepharitis, H2 2011 7
Products under Development for Blepharitis – Comparative Analysis, H2 2011 8
Products under Development by Companies, H2 2011 9
Products under Investigation by Universities/Institutes, H2 2011 10
Late Stage Products, H2 2011 11
Mid Clinical Stage Products, H2 2011 12
Early Clinical Stage Products, H2 2011 13
Pre-Clinical Stage Products, H2 2011 14
Assessment by Monotherapy Products, H2 2011 19
Assessment by Route of Administration, H2 2011 20
Assessment by Stage and Route of Administration, H2 2011 21
Assessment by Molecule Type, H2 2011 22
Assessment by Stage and Molecule Type, H2 2011 23